CurrentHealth NetPolicy CP PHAR.58

Clinical Policy: Denosumab (Prolia, Xgeva)

Medical necessity policy for denosumab products and biosimilars (Prolia, Xgeva and listed biosimilars) covering indications, initial and continued therapy criteria, dosing limits, exclusions, prior authorization and approval durations for Commercial, HIM and Medicaid lines of business.

Policy Summary

PayerHealth Net

PolicyClinical Policy: Denosumab (Prolia, Xgeva)

Policy CodePolicy CP PHAR.58

Change TypeAdded biosimilarsboxed warning updatecriteria refinements

Effective Date03.01.11

Next Review Date

Key ActionProvider must submit office chart notes, lab results or other clinical information supporting that member meets all approval criteria; prior authorization may be required.

SourceLink

POLICY UPDATE CHANGES

Added multiple new biosimilars (Jubbonti, Wyost, denosumab-dssb, Osenvelt, Ospomyv, Stoboclo, Xbryk, denosumab-bnht, Bomyntra, Conexxence) to policy criteria during 2024-2025 updates.

Added boxed warning for severe hypocalcemia in patients with advanced kidney disease per updated Prolia and Jubbonti prescribing information.

For prostate and breast cancer fracture prevention, added requirement that member does not have bone metastasis.

For giant cell tumor of bone, removed localized disease combination use with interferon alfa per NCCN guidance.

Added HCPCS code Q5136 for denosumab biosimilar (Jubbonti/Wyost) to coding list.

2Primary dose regimens (60 mg q6mo; 120 mg q4wk)

5Major covered indication groups

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

>=18Minimum age for coverage unless closed epiphyses documented

Coverage Summary

This policy is a medical necessity coverage policy for denosumab products and listed biosimilars (including Prolia, Xgeva, and biosimilars such as Jubbonti, Wyost, denosumab-dssb/Ospomyv/Xbryk, Osenvelt/Stoboclo, denosumab-bnht/Bomyntra/Conexxence) and applies to Commercial, HIM and Medicaid lines of business. It covers the major indication groups: osteoporosis (postmenopausal, glucocorticoid‑induced, and male osteoporosis), prostate/breast cancer fracture prevention, multiple myeloma and solid tumor bone metastases, giant cell tumor of bone, and hypercalcemia of malignancy.

Dosing regimens are specified by product group: Prolia and osteoporosis biosimilars: 60 mg subcutaneously every 6 months; Xgeva and oncology biosimilars: 120 mg subcutaneously every 4 weeks (with additional 120 mg doses on days 8 and 15 of the first month for some oncology indications). Coverage is provided with clinical criteria, prior‑therapy requirements, dosing limits, and prior authorization/documentation expectations.

Key thresholds & quick facts

Albumin-corrected calcium threshold>= 12.5 mg/dL (for hypercalcemia of malignancy despite IV bisphosphonate in last 30 days)

BMD T-score thresholds (very high risk)< -3.0 at hip or spine, or <= -2.5 with a major osteoporotic fracture

Minimum age for coverage>= 18 years (or documentation of closed epiphyses on X-ray)

HCPCS codes listed (count)2 codes listed (J0897 and Q5136)

Policy identifier and datesPolicy: CP PHAR.58 — Effective: 03.01.11; Last review: 02.25; Status: CURRENT

Initial Therapy Criteria — Osteoporosis (Prolia & specified biosimilars)

Initial Therapy Criteria — Prostate/Breast Cancer Fracture Prevention (Prolia & specified biosimilars)

Initial Therapy Criteria — Multiple Myeloma / Solid Tumor (Xgeva & oncology biosimilars)

Initial Therapy Criteria — Giant Cell Tumor of Bone (Xgeva & oncology biosimilars)

Initial Therapy Criteria — Hypercalcemia of Malignancy (Xgeva & oncology biosimilars)

Initial Therapy Criteria — Systemic Mastocytosis (off‑label, oncology biosimilars)

Initial Approval Criteria - Systemic Mastocytosis (off-label) (Xgeva and oncology biosimilars)

All of the following must be met:

ALL of the following

Request is for Xgeva, Bomyntra, Osenvelt, Wyost, Xbryk, or denosumab-bnht
Diagnosis of systemic mastocytosis
Clinical requirement: Member has osteopenia or osteoporosis with bone pain
Age/epiphyses: Age ≥ 18 years OR documentation of closed epiphyses on X-ray

Other Indications / Off‑Label Requests

Continuation Therapy Criteria

Provider Actions & Operational Requirements

Prior Authorization

Submit documentation for approval

Provider must submit office chart notes, laboratory results, or other clinical information supporting that the member meets all approval criteria. Prior authorization may be required for bisphosphonates and denosumab per line of business; bisphosphonate prior authorization may apply.

Documentation Required

Age / skeletal maturity documentation

Provide documentation of age ≥ 18 years or radiographic evidence of closed epiphyses (X‑ray) when requested to demonstrate skeletal maturity.

Applicable Codes

HCPCS - Denosumab injectionHCPCS

J0897	Injection, denosumab, 1 mg
Q5136	Injection, denosumab-bbdz (Jubbonti/Wyost biosimilar), 1 mg

Clinical Evidence & Background

Denosumab products (Prolia, Xgeva) and the listed biosimilars are RANKL (receptor activator of nuclear factor kappa‑B ligand) inhibitors. FDA‑labeled indications include treatment of postmenopausal osteoporosis, increasing bone mass in men with osteoporosis, glucocorticoid‑induced osteoporosis, fracture prevention in patients receiving ADT for nonmetastatic prostate cancer and in women receiving adjuvant aromatase inhibitor therapy for breast cancer, prevention of skeletal‑related events in multiple myeloma and bone metastases, treatment of giant cell tumor of bone, and treatment of hypercalcemia of malignancy refractory to bisphosphonates.

The policy aligns coverage with FDA indications and guideline‑based definitions of fracture risk (for example, AACE/ACE and WHO T‑score definitions are used). For osteoporosis and many other indications the policy requires prior trial and failure of bisphosphonate therapy (generic alendronate preferred) at maximally indicated doses unless one of the documented bypass conditions applies (for example, contraindication to all bisphosphonates, clinically significant adverse effects to both oral and IV bisphosphonates, loss of BMD or lack of BMD increase after ≥12 months of bisphosphonate therapy, or an osteoporotic/fragility fracture while on bisphosphonate therapy).

Per updated prescribing information and policy revisions, boxed warnings note that CKD‑MBD markedly increases the risk of severe hypocalcemia and that patients with advanced chronic kidney disease are at greater risk; the policy advises evaluation for CKD‑MBD prior to initiating Prolia (and certain biosimilars) and supervision by a provider experienced in CKD‑MBD where applicable.

The policy also incorporates guideline and regulatory considerations for oncology settings (including state‑level prohibitions on step therapy for certain metastatic cancer scenarios) when applying prior‑therapy requirements.

Evidence highlights

Revision History

03.06.25material change - added biosimilars

RT4 addition of multiple new biosimilars (denosumab-dssb, Osenvelt, Ospomyv, Stoboclo, Xbryk) to policy criteria.

04.14.25material change - added biosimilars

RT4 addition of additional biosimilars (denosumab-bnht, Bomyntra, Conexxence) to policy criteria.

1Q2025 (P&T Approval Date 02.25)material change - boxed warning and CKD-MBD guidance

Oncology prescriber: Prescribed by or in consultation with an oncologist

Prior therapy requirement or exceptions

Failure of zoledronic acid OR pamidronate at up to maximally indicated doses unless contraindicated or adverse effects
See Appendices B and D
Request is for the treatment associated with cancer for a State with regulations against step therapy in certain oncology settings (see Appendix E)

Dose support: Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence)FDA maximum or guideline-supported

Prescriber must submit evidence

Regimen requirement: Regimen must be FDA-approved or recommended by NCCN

Exclusion: Not prescribed concurrently with Prolia or osteoporosis denosumab products

Billing Rule

Dosing limits

Dosing limits: do not exceed 60 mg every 6 months for Prolia and osteoporosis denosumab products; do not exceed 120 mg every 4 weeks for Xgeva and oncology denosumab products. For oncology indications that require the initial loading schedule, include additional 120 mg doses on days 8 and 15 of the first month of therapy where specified.

Affected HCPCS codes: J0897, Q5136
Osteoporosis products (Prolia and listed biosimilars): 60 mg SC once every 6 months (max 60 mg/dose)
Oncology products (Xgeva and oncology biosimilars): 120 mg SC once every 4 weeks (max 120 mg/dose); initial month may include 120 mg on days 8 and 15

Step Therapy

Bisphosphonate trial requirement or documented bypass

Require trial and failure of a preferred bisphosphonate (generic alendronate preferred) at up to maximally indicated doses unless contraindicated or clinically significant adverse effects occur. Allow documented bypass if any of the following apply: clinically significant adverse effects to both IV and oral bisphosphonates; all bisphosphonates are contraindicated; loss of BMD while on bisphosphonate therapy; lack of BMD increase after ≥ 12 months of bisphosphonate therapy; or occurrence of an osteoporotic/fragility fracture while receiving bisphosphonate therapy. State-specific prohibitions on step therapy for certain metastatic or advanced cancer settings (see Appendix E) may permit bypassing step therapy.

Preferred trial: generic alendronate at maximally indicated doses (unless contraindicated)
Bypass conditions: adverse effects to both IV and PO bisphosphonates; all bisphosphonates contraindicated; loss of BMD on bisphosphonate therapy; no BMD increase after ≥ 12 months of therapy; osteoporotic/fragility fracture while on therapy
State exceptions: Appendix E lists states where step therapy is prohibited for stage 4/advanced metastatic cancer and related conditions

Documentation Required

Oncology prescribing

Oncology indications must be prescribed by or in consultation with an oncologist. For certain cancer-related requests, state regulations against step therapy in specified metastatic/advanced cancer settings (see Appendix E) may allow bypass of prior therapy requirements.

AACE/ACE 2020 definition used'Very high fracture risk' definition per 2020 AACE/ACE guidelines is used to inform criteria (T-score-based definitions referenced)

Prolia prescribing info update (boxed warning)Boxed warning: patients with advanced chronic kidney disease are at increased risk of severe hypocalcemia; evaluate for CKD-MBD prior to initiation and supervise treatment by a provider experienced in CKD-MBD

High risk of fracture: defined in the policy as a history of osteoporotic fracture, multiple risk factors for fracture, or failure/intolerance to other available osteoporosis therapy (policy definition of the term used to operationalize FDA and guideline language).

ADT (Androgen Deprivation Therapy): defined/abbreviated in the policy Appendix as androgen deprivation therapy (examples cited in criteria: leuprolide, bicalutamide, nilutamide) used in prostate cancer fracture‑prevention criteria.

BMD T‑score: Bone mineral density T‑score per WHO (operational diagnostic threshold used by guidelines); osteoporosis is ≤ -2.5 and the policy uses T‑score thresholds (e.g., < -3.0 for very high risk or ≤ -2.5 with a major osteoporotic fracture) in coverage criteria.

CKD‑MBD: chronic kidney disease–mineral bone disorder; the policy highlights that CKD‑MBD increases hypocalcemia risk with Prolia and certain biosimilars and requires evaluation prior to initiation in advanced CKD per boxed warning language.

1Q2025 annual review: added boxed warning for severe hypocalcemia in patients with advanced CKD and requirement to evaluate for CKD-MBD and supervision by a provider experienced in CKD-MBD prior to initiating Prolia and specified biosimilars.

1Q2025 (P&T Approval Date 02.25)material change - indication criteria revision

1Q2025 annual review: for prostate and breast cancer fracture prevention, added requirement that the member does not have bone metastasis.

1Q2025 (P&T Approval Date 02.25)material change - NCCN alignment

1Q2025 annual review: aligned with NCCN by removing combination use of interferon alfa for localized giant cell tumor of bone.

08.07.24non-material change - coding updateLatest

Added HCPCS code Q5136 for denosumab-bbdz (Jubbonti/Wyost biosimilar) to coding list.